Bamboo Therapeutics

The funding will be for a GLP-1 receptor agonist clinical programme for weight loss

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity

There are currently no approved human vaccines for Lyme disease

Litfulo delivered significant, clinically meaningful improvements for both face and body

The phase 3 trial showed greater than 50% improvement in radiographic progression-free survival

The real-world findings support the long-term benefits of continuous treatment

Pompe disease is a rare, progressive neuromuscular disease, with infantile onset being the most aggressive form

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival

SPMS is a debilitating stage of MS where patients experience increasing levels of disability

The acquisition will expand the company’s immunology pipeline

Fontoura previously held senior leadership roles at Xaira Therapeutics and Roche